IMMUNOREACTIVITY FOR P53 PROTEIN IN MALIGNANT MESOTHELIOMA AND NONNEOPLASTIC MESOTHELIUM

被引:57
|
作者
RAMAEL, M
LEMMENS, G
EERDEKENS, C
BUYSSE, C
DEBLIER, I
JACOBS, W
VANMARCK, E
机构
[1] Department of Pathology, University Hospital Antwerp, University of Antwerp (U.I. A.), Edegem, 2650
来源
JOURNAL OF PATHOLOGY | 1992年 / 168卷 / 04期
关键词
MESOTHELIOMA; P53; PROTEIN; SUPPRESSOR ONCOGENE; IMMUNOHISTOCHEMISTRY; MESOTHELIUM;
D O I
10.1002/path.1711680406
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The presence of p53 protein in non-neoplastic pleural mesothelium (40 cases) and in human malignant mesothelioma (36 cases) was assessed immunohistochemically using the antibodies DO7, CM-1, and PAb240. In a quarter of the malignant mesotheliomas, there was nuclear immunoreactivity for p53 protein with both the DO7 and CM-I antibodies. There were no statistically significant differences between the various mesothelioma subtypes (P>0.05). No immunoreactivity was found with the PAb240 antibody, suggesting absence of mutant-type p53 protein. Non-neoplastic mesothelium was not immunoreactive with any of the antibodies. We conclude that there is immunoreactivity for p53 protein in some mesotheliomas. p53 protein immunoreactivity could be used to discriminate between neoplastic and reactive mesothelium.
引用
收藏
页码:371 / 375
页数:5
相关论文
共 50 条
  • [1] IMMUNOREACTIVITY FOR BCL-2 PROTEIN IN MALIGNANT MESOTHELIOMA AND NONNEOPLASTIC MESOTHELIUM
    SEGERS, K
    RAMAEL, M
    KUMAR-SINGH, S
    WEYLER, J
    VANMEERBEECK, J
    VERMEIRE, P
    VANMARCK, E
    [J]. VIRCHOWS ARCHIV, 1994, 424 (06) : 631 - 634
  • [2] Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma
    Segers, K
    Backhovens, H
    Kumar-Singh, S
    DeVoecht, J
    Ramael, M
    Van Broeckhoven, C
    VanMarck, E
    [J]. VIRCHOWS ARCHIV, 1995, 427 (04) : 431 - 436
  • [3] Activation of p53 in Malignant Mesothelioma
    Singh, Anand
    Bhattacharyya, Nisan
    Srivastava, Abhishek
    Zhang, Li
    Schrump, David
    Hoang, Chuong
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1349 - S1350
  • [4] IMMUNOREACTIVITY FOR THE BETA-CHAIN OF THE PLATELET-DERIVED GROWTH-FACTOR RECEPTOR IN MALIGNANT MESOTHELIOMA AND NONNEOPLASTIC MESOTHELIUM
    RAMAEL, M
    BUYSSE, C
    VANDENBOSSCHE, J
    SEGERS, K
    VANMARCK, E
    [J]. JOURNAL OF PATHOLOGY, 1992, 167 (01): : 1 - 4
  • [5] P53 EXPRESSION IS COMMON IN MALIGNANT MESOTHELIOMA
    KAFIRI, G
    THOMAS, DM
    SHEPHERD, NA
    KRAUSZ, T
    LANE, DP
    HALL, PA
    [J]. HISTOPATHOLOGY, 1992, 21 (04) : 331 - 334
  • [6] IMMUNOREACTIVITY FOR P-170 GLYCOPROTEIN IN MALIGNANT MESOTHELIOMA AND IN NONNEOPLASTIC MESOTHELIUM OF THE PLEURA USING THE MURINE MONOCLONAL-ANTIBODY JS']JSB-1
    RAMAEL, M
    VANDENBOSSCHE, J
    BUYSSE, C
    VANMEERBEECK, J
    SEGERS, K
    VERMEIRE, P
    VANMARCK, E
    [J]. JOURNAL OF PATHOLOGY, 1992, 167 (01): : 5 - 8
  • [7] P53 IMMUNOREACTIVITY IN CERVICAL INTRAEPITHELIAL NEOPLASIA AND NONNEOPLASTIC CERVICAL SQUAMOUS EPITHELIUM
    JEFFERS, MD
    RICHMOND, J
    FARQUHARSON, M
    MCNICOL, AM
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1994, 47 (12) : 1073 - 1076
  • [8] Mesothelium and Malignant Mesothelioma
    Hiriart, Emilye
    Deepe, Raymond
    Wessels, Andy
    [J]. JOURNAL OF DEVELOPMENTAL BIOLOGY, 2019, 7 (02):
  • [9] EXPRESSION OF P53 IN REACTIVE MESOTHELIUM
    DOWELL, S
    DERIAS, N
    WILSON, POG
    LANE, DP
    HALL, PA
    [J]. HISTOPATHOLOGY, 1993, 22 (01) : 96 - 97
  • [10] P16 and p53 protein expression in malignant mesothelioma and mesothelial proliferative processes
    Valladares, M.
    Lujan, D. R.
    Avila, R.
    Santos, A.
    Gomez, L.
    [J]. VIRCHOWS ARCHIV, 2013, 463 (02) : 244 - 244